BSW Wealth Partners decreased its holdings in shares of CVS Health Corporation (NYSE:CVS) by 16.7% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm owned 2,627 shares of the pharmacy operator’s stock after selling 526 shares during the period. BSW Wealth Partners’ holdings in CVS Health Corporation were worth $206,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Mercer Capital Advisers Inc. bought a new stake in CVS Health Corporation during the first quarter valued at $118,000. SRS Capital Advisors Inc. boosted its stake in CVS Health Corporation by 48.2% during the first quarter. SRS Capital Advisors Inc. now owns 2,256 shares of the pharmacy operator’s stock valued at $177,000 after buying an additional 734 shares during the period. Cue Financial Group Inc. boosted its stake in CVS Health Corporation by 3.6% during the first quarter. Cue Financial Group Inc. now owns 2,708 shares of the pharmacy operator’s stock valued at $213,000 after buying an additional 95 shares during the period. Pettee Investors Inc. bought a new stake in CVS Health Corporation during the first quarter valued at $214,000. Finally, Diversified Trust Co bought a new stake in CVS Health Corporation during the first quarter valued at $229,000. 81.55% of the stock is owned by institutional investors.

COPYRIGHT VIOLATION NOTICE: “CVS Health Corporation (CVS) Shares Sold by BSW Wealth Partners” was first reported by Daily Political and is the sole property of of Daily Political. If you are viewing this article on another publication, it was illegally stolen and reposted in violation of United States and international trademark & copyright laws. The legal version of this article can be read at https://www.dailypolitical.com/2017/09/13/cvs-health-corporation-cvs-shares-sold-by-bsw-wealth-partners.html.

CVS Health Corporation (NYSE:CVS) traded up 0.79% on Wednesday, hitting $83.08. The company’s stock had a trading volume of 3,339,426 shares. The firm has a 50 day moving average of $78.56 and a 200 day moving average of $78.91. CVS Health Corporation has a 12 month low of $69.30 and a 12 month high of $91.13. The firm has a market cap of $84.46 billion, a price-to-earnings ratio of 16.55 and a beta of 0.92.

CVS Health Corporation (NYSE:CVS) last posted its quarterly earnings results on Tuesday, August 8th. The pharmacy operator reported $1.33 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $1.31 by $0.02. CVS Health Corporation had a net margin of 2.93% and a return on equity of 17.47%. The firm had revenue of $45.69 billion during the quarter, compared to the consensus estimate of $45.36 billion. During the same quarter in the previous year, the firm posted $1.32 earnings per share. The company’s revenue was up 4.5% on a year-over-year basis. Equities research analysts forecast that CVS Health Corporation will post $5.88 earnings per share for the current fiscal year.

In related news, CFO David M. Denton sold 237,078 shares of CVS Health Corporation stock in a transaction that occurred on Monday, September 11th. The shares were sold at an average price of $79.65, for a total transaction of $18,883,262.70. Following the transaction, the chief financial officer now directly owns 141,096 shares of the company’s stock, valued at $11,238,296.40. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, EVP Helena Foulkes sold 20,332 shares of CVS Health Corporation stock in a transaction that occurred on Monday, June 19th. The shares were sold at an average price of $76.98, for a total transaction of $1,565,157.36. Following the transaction, the executive vice president now directly owns 59,300 shares in the company, valued at $4,564,914. The disclosure for this sale can be found here. Over the last three months, insiders have sold 370,510 shares of company stock worth $29,460,266. 0.61% of the stock is currently owned by corporate insiders.

CVS has been the subject of several research analyst reports. Vetr raised CVS Health Corporation from a “buy” rating to a “strong-buy” rating and set a $85.96 price target for the company in a research note on Wednesday, May 17th. Needham & Company LLC reaffirmed a “hold” rating on shares of CVS Health Corporation in a research note on Sunday. ValuEngine lowered CVS Health Corporation from a “buy” rating to a “hold” rating in a research note on Friday, June 2nd. BidaskClub lowered CVS Health Corporation from a “hold” rating to a “sell” rating in a research note on Friday, August 25th. Finally, Guggenheim reaffirmed a “buy” rating on shares of CVS Health Corporation in a research note on Monday, July 3rd. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and fourteen have given a buy rating to the company’s stock. CVS Health Corporation has an average rating of “Buy” and an average price target of $90.14.

CVS Health Corporation Company Profile

CVS Health Corporation, together with its subsidiaries, is an integrated pharmacy healthcare company. The Company provides pharmacy care for the senior community through Omnicare, Inc (Omnicare) and Omnicare’s long-term care (LTC) operations, which include distribution of pharmaceuticals, related pharmacy consulting and other ancillary services to chronic care facilities and other care settings.

Institutional Ownership by Quarter for CVS Health Corporation (NYSE:CVS)

Receive News & Ratings for CVS Health Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health Corporation and related companies with MarketBeat.com's FREE daily email newsletter.